Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells 1,577 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 1,577 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $39,425.00. Following the completion of the sale, the chief marketing officer now owns 104,961 shares in the company, valued at $2,624,025. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The stock was sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Down 4.6 %

Shares of BLFS stock traded down $1.21 during trading on Thursday, reaching $25.06. The company’s stock had a trading volume of 278,326 shares, compared to its average volume of 349,466. The stock’s 50-day moving average price is $26.64 and its 200 day moving average price is $25.51. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -23.64 and a beta of 2.04. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. On average, research analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Hedge Funds Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of BLFS. Principal Financial Group Inc. boosted its stake in shares of BioLife Solutions by 4.7% during the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock valued at $4,776,000 after acquiring an additional 8,580 shares during the last quarter. Curi RMB Capital LLC raised its holdings in BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after acquiring an additional 2,283 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth $57,000. Intech Investment Management LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth $255,000. Finally, Charles Schwab Investment Management Inc. increased its stake in BioLife Solutions by 3.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 319,959 shares of the medical equipment provider’s stock valued at $8,012,000 after purchasing an additional 9,750 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BLFS shares. Northland Securities increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. TD Cowen increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright upped their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Benchmark restated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.